Novartis raises outlook, maps out Sandoz spin-off
Novartis raises outlook, maps out Sandoz spin-off
Finance
Bausch + Lomb to buy dry-eye drug from Novartis for $1.75 billion - WSJ
Bausch + Lomb to buy dry-eye drug from Novartis for $1.75 billion - WSJ
Finance,Mergers
Novartis names Sandoz board members ahead of spin-off
Novartis names Sandoz board members ahead of spin-off
Finance,Health
Terms of Service | Privacy Policy
© 2024 Sosao • Com